Product image of Icatibant Sandoz (Icatibant) supplied by GNH India

Icatibant Sandoz

Active Ingredient:
Icatibant
Origin:
EU

Icatibant Sandoz (Icatibant)

Icatibant, the active ingredient in Icatibant Sandoz, is a bradykinin B2 receptor antagonist presented as a subcutaneous formulation for subcutaneous use. It is indicated for the treatment of hereditary angioedema attacks in patients with C1‑inhibitor deficiency.

GNH India supplies Icatibant Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier, providing quality‑assured products to hospitals, pharmacies and clinics worldwide. The company follows stringent manufacturing standards and offers reliable logistics for global distribution.

Manufacturer / TM Owner

Sandoz A/S

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Icatibant is used to manage hereditary angioedema, a disorder characterized by sudden swelling due to bradykinin excess.

  • Hereditary angioedema (C1‑inhibitor deficiency) attacks: rapid reduction of swelling and pain during acute episodes.
  • Hereditary angioedema type I: shortens the duration of attacks and improves patient comfort.
  • Hereditary angioedema type II: facilitates faster symptom resolution in acute flare‑ups.

How It Works

  • Icatibant acts as a competitive antagonist at the bradykinin B2 receptor. By binding to this G‑protein‑coupled receptor, it blocks the effects of endogenous bradykinin, preventing vasodilation and increased vascular permeability that cause swelling. The inhibition of the B2 receptor thereby reduces the formation of edema and associated pain during hereditary angioedema attacks.

Side Effects

Icatibant may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Injection site pain: discomfort at the site of subcutaneous administration.
  • Redness at injection site: localized erythema.
  • Swelling at injection site: mild edema around the needle entry.
  • Nausea: transient feeling of queasiness.
  • Headache: mild to moderate head pain.
  • Flushing: temporary warmth and reddening of skin.

Serious or Rare Side Effects

  • Anaphylaxis: severe allergic reaction requiring immediate medical attention.
  • Angioedema: unexpected swelling of face, lips, or airway.
  • Hypotension: sudden drop in blood pressure.
  • Severe injection site reaction: necrosis or ulceration.
  • Thrombocytopenia: low platelet count observed in rare cases.

Precautions & Warnings

When prescribing Icatibant, clinicians should consider several safety precautions to minimize risk.

  • Pregnancy: safety not established; use only if potential benefit justifies the risk.
  • Breastfeeding: unknown excretion; weigh benefits against possible infant exposure.
  • Renal impairment: no dosage adjustment required, but monitor for accumulation.
  • Concomitant ACE inhibitors: may increase risk of angioedema; observe closely.
  • Hypersensitivity: discontinue immediately if severe allergic reaction occurs.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Icatibant can interact with other medicines, affecting its safety or efficacy.

Major Interactions (Avoid)

  • ACE inhibitors: combined use may heighten risk of angioedema.
  • Renin‑angiotensin system blockers (ARBs, aliskiren): similar potential for increased angioedema.
  • Other bradykinin B2 antagonists: additive pharmacologic effect may lead to excessive blockade.

Moderate Interactions (Monitor Closely)

  • Estrogen‑containing contraceptives: may influence bradykinin metabolism, requiring observation.
  • NSAIDs: can exacerbate swelling or pain in susceptible individuals.
  • DPP‑4 inhibitors: theoretical risk of altered bradykinin degradation; monitor clinical response.

Frequently Asked Questions

Icatibant Sandoz is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in patients with C1‑inhibitor deficiency. It helps to rapidly reduce swelling and associated discomfort during an HAE episode.

Icatibant works by competitively blocking the bradykinin B2 receptor, a key mediator of vasodilation and vascular permeability. By preventing bradykinin from binding, it limits the swelling and pain that characterize hereditary angioedema attacks.

The dose of Icatibant is determined by the prescribing clinician based on the patient’s condition and regulatory guidelines. Dosing instructions are provided on the prescription label and should not be altered without medical advice.

Safety data for Icatibant during pregnancy and lactation are limited. It should be used only if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To order Icatibant Sandoz, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

The primary alternative for HAE is plasma‑derived or recombinant C1‑inhibitor concentrate. While C1‑inhibitors replace the deficient protein, Icatibant directly blocks bradykinin’s action. Icatibant offers a rapid subcutaneous route, whereas C1‑inhibitors are administered intravenously and may have different storage requirements.

Icatibant Sandoz should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. Do not use the medication if it has been exposed to temperatures outside this range.

Icatibant is given as a subcutaneous injection, typically into the abdomen or thigh. The injection is performed by a trained healthcare professional or, in some cases, by the patient after appropriate instruction. The site should be rotated for repeated administrations.

Serious risks include anaphylaxis, unexpected angioedema of the face or airway, severe hypotension, and rare hematologic events such as thrombocytopenia. Patients should be monitored closely after the first dose and instructed to seek immediate medical attention if any severe reaction occurs.

Icatibant is contraindicated in individuals with known hypersensitivity to icatibant or any of its excipients. Caution is advised for patients with a history of severe allergic reactions, and it should be avoided in combination with other bradykinin B2 antagonists unless specifically directed by a physician.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Icatibant

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT